The US Food and Drug Administration has granted approval to PrecivityAD2, the first blood test cleared to detect Alzheimer’s disease in adults starting at age 40 who show cognitive symptoms. This advancement could transform early diagnosis and treatment for millions affected by Alzheimer’s.
- Detects Alzheimer’s biomarkers with 97.6% accuracy
- Available for symptomatic adults aged 40 and older
- Offers a less invasive alternative to PET scans or lumbar punctures
What happened
The US Food and Drug Administration (FDA) has cleared PrecivityAD2, a blood test that detects Alzheimer’s disease (AD) biomarkers in adults as young as 40 who exhibit cognitive symptoms. This test is the first of its kind approved for this younger age group, representing a milestone in early diagnostic tools for AD.
PrecivityAD2 works by analyzing blood plasma to measure amyloid and tau proteins, key indicators of Alzheimer’s pathology, using advanced mass spectrometry. The test then categorizes results as negative, likely positive, or positive, assisting clinicians in diagnosis without the need for invasive procedures.
Why it feels good
For years, diagnosing Alzheimer's required complex procedures such as PET imaging or lumbar punctures, which are costly and uncomfortable. This new blood test offers a simpler, quicker, and less invasive alternative, reducing barriers to early diagnosis for many patients.
Early detection is critical because Alzheimer’s begins developing long before symptoms appear. By identifying individuals at an earlier stage, doctors can initiate treatments sooner, potentially slowing disease progression. This innovation also improves the accuracy of clinical trials and supports tailored therapies.
What to enjoy or watch next
With PrecivityAD2 now FDA-approved and entering clinical practice, more symptomatic adults can access early Alzheimer's testing, which might lead to personalized care plans and improved quality of life. Researchers and healthcare providers will be watching closely to see how widely this test is adopted and its impact on patient outcomes.
Future developments may include combining blood test results with emerging therapies to provide targeted treatment options. Advances in Alzheimer's research continue to accelerate, fueled by technologies like PrecivityAD2 that promise broader access to timely and reliable diagnosis.